Minimizing Diabetes-Related Complications and Increasing Glycemic Control: Appropriate Glycemic Screening and Assessment and the Selection of Non-insulin Therapies Based on Safety, Efficacy, and Pathophysiological Targets

**Bibliography**


Buse J. IDeGliRa, a Novel Fixed Ratio Combination of Insulin Degludec and Liraglutide, is Efficacious and Safe in Subjects with Type 2 Diabetes: A Large, Randomized Phase 3 Trial. Presented at: The 73rd American Diabetes Association Scientific Sessions; June 21-25, 2014; Chicago, IL.


Flood TM. Appropriate use of insulin analogs in an increasingly complex type 2 diabetes mellitus (T2DM) landscape. *J Fam Pract.* 2007;56(suppl 1):S1-S12.


Marre M, Shaw J, Brändle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26:268-278.


Wright AD, Cull CA, MacLeod KIM, Hollman RR, UKPDS Group. Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. J Diabetes Complications. 2006;20:395-401.


